EUVIMEDEUVIMED entdecken
Crossref

Haemodynamic, oxygenation, and ventilation targets after cardiac arrest: the current ABC of post-cardiac arrest intensive care

Jesper Kjaergaard iD, Jacob Eifer Møller

European Heart Journal: Acute Cardiovascular Care · 2023

DOI: 10.1093/ehjacc/zuad077 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Heart Journal: Acute Cardiovascular Care, 2023. Verfasst von Jesper Kjaergaard und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The Heart Center, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, Copenhagen 2100, Denmark. Hauptthemen laut MEDLINE: Heart Arrest, Cardiopulmonary Resuscitation, Hypothermia, Induced, Out-of-Hospital Cardiac Arrest. Die Arbeit nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients remaining in coma after having been resuscitated from out-of-hospital cardiac arrest (OHCA) frequently require intensive care. These patients are usually managed by a guideline-recommended, goal-directed approach to support and maintain organ function.1 Since hypoxic brain injury is the leading cause of death in these patients,2 neuroprotective strategies and interventions have been implemented and investigated. In fact, post-resuscitation care has come to represent a bundle of strategies and goal-directed interventions administered over the first 2–5 days following cardiac arrest.1 While research in post-cardiac arrest care of OHCA patients has been dominated by targeted temperature management (TTM) and neurological prognostication,1 the other aspects of optimizing therapy have received less scientific attention. Targeted temperature management was originally implemented after two randomized clinical trials were published in 2002, reporting the clinical benefits of lowering body temperature to 33°C for 12–24 h.3,4 These trials were unspecific in terms of guiding the other aspects of post-cardiac arrest care in the intensive care setting. Later trials in TTM have been pragmatic, and the results have questioned the benefits of mild-to-moderate hypothermia in the immediate post-resuscitation phase.5,6 Although ischaemic heart disease is the underlying cause of cardiac arrest in many OHCA patients , an initial diagnostic approach of immediate coronary angiography in patients suspected with an acute myocardial infarction ST segment myocardial infarction has also been challenged.7 Therefore, contemporary patient management is largely based on intensive supportive care and most centres have standardized protocols for supporting airway, breathing, and circulation for patients remaining in coma after cardiac arrest. Both American and European guidelines have provided recommendations on treatment targets in post-resuscitation care but have made it clear that evidence is less.1,8 This review seeks to provide an overview of current evidence and guidelines on goals for intensive care for the initial days of post-cardiac arrest. Table 1 provides an overview of the recent randomized trials conducted. Overview of recent randomized trials in managing comatose cardiac arrest survivors CPC, cerebral performance category; mRS, modified Rankin scale; OHCA, out-of-hospital cardiac arrest; TTM, targeted temperature management; NSE, neuron-specific enolase. Overview of recent randomized trials in managing comatose cardiac arrest survivors CPC, cerebral performance category; mRS, modified Rankin scale; OHCA, out-of-hospital cardiac arrest; TTM, targeted temperature management; NSE, neuron-specific enolase. Protection of airways with endotracheal intubation is usually needed in patients undergoing TTM after spontaneous circulation has been restored,1 since the lack of consciousness after Return of Spontaneous Circulation (ROSC) is a major factor for the indication of TTM. Whether orotracheal intubation should be performed prior to hospitalization is highly controversial.9 Guidelines generally agree that endotracheal intubation for treating cardiac arrest is preferable over the use of laryngeal devices and mask ventilation.1 Two randomized trials have not provided evidence that laryngeal tubes are preferable over pre-hospital endotracheal intubation in the OHCA setting in terms of differences in outcomes,9,10 as laryngeal tube insertion was associated with a greater survival rate of up to 72 h and up to hospital discharge in one trial.9 However, this result should be interpreted in the light of unsuccessful endotracheal intubation in 44% of patients in the group who were planned to undergo endotracheal intubation, which may be associated with an increased rate of adverse outcomes in this group.9 It is likely that an organization with emergency physicians with great experience in intubation and managing airways will result in higher rates of successful intubation as seen in the BOX trial, where successful pre-hospital intubation was achieved in >90% of patients.11 Guidelines support the use of controlled ventilation in comatose patients for airway protection and to allow for controlled ventilation.1 The duration of mechanical ventilation and TTM was investigated in the TTH trial reported by Kirkegaard et al.12, which showed similar survival rates comparing a sedation duration of 24–48 h, thus indirectly comparing prolonged mechanical ventilation with conventional awakening after 24 h. Early awakening is being investigated in two large-scale trials, the DANOHCA (NCT05895838) and SEDCARE (NCT05564754) trials, both comparing short-term/minimal sedation with the guidelines based on 24 h or more of sedation as implemented with TTM. Patients remaining unconscious (Glasgow Coma Scale score of 8 or less) should have a safe airway during resuscitation or immediately after return of spontaneous circulation. A safe airway could be a laryngeal tube or endotracheal intubation in the pre-hospital setting. The choice should depend on local organization and experience in endotracheal intubation in emergency medical staff managing airways in the pre-hospital setting. In patients in whom a laryngeal device is used in the pre-hospital setting, endotracheal intubation at hospital arrival is recommended to avoid further aspiration and to be able to provide optimal ventilation for the duration of TTM. Mechanical ventilation is needed in patients remaining comatose after the return of spontaneous circulation. The target for oxygenation should be an oxygen saturation of 94–98% or an arterial partial pressure of 10–13 kPa (Figure 1). Both hypoxia and hyperoxia should be avoided.1 Guidelines recommend against hyperventilation and targeting a partial pressure of CO2 of 4.5–6.9 kPa. Ventilation should be lung protective of 6–8 mL/kg ideal body weight.1 Summary of treatment targets in the early phase managing comatose patients resuscitated from out-of-hospital cardiac arrest managed in the intensive care unit. MAP, mean arterial blood pressure; PaCO2, partial arterial carbon dioxide pressure; PaO2, partial arterial oxygen pressure; RASS, Richmond Agitation and Sedation Scale; SatO2, arterial oxygen saturation; SVO2, mixed or central venous oxygen saturation; TV, tidal volume. Created with BioRender.com. During the low-flow period, hypoxia is likely to develop and will be a major detrimental part of the organ injury associated with cardiac arrest, where hypoxic brain injury is the predominant mode of death.2 The use of 100% inspired oxygen during resuscitation is recommended and seems reasonable in cases with profound hypoxaemia, but it is unclear whether this can lead to harmful hypoxaemia. After the return of spontaneous circulation and during TTM, it is believed that both hypoxia and hyperoxia, among other factors, may contribute to brain injury.13 On the other hand, exploratory analyses of the TTM cohort were unable to identify the thresholds of PaO2 where there was an increase in mortality rates.14 The detrimental effects of both hypoxia and hyperoxia were more visible in a post-hoc analysis of the TTM2 cohort.15 For critically ill patients in the intensive care unit (ICU), a benefit of conservative oxygenation strategy was also suggested in the subgroup of patients with hypoxic encephalopathy in the OXY-ICY trial.16 A pilot study that investigated hyperoxia (20–25 kPa) vs. normoxia (10–15 kPa) in 120 patients suggested no significant difference in the serum concentration of neuron-specific enolase (NSE) after 48 h, which was the primary outcome of the trials.17 Recently, the BOX trial was published after having randomized 789 comatose OHCA patients to either restrictive (9–10 kPa) or liberal (13–14 kPa) oxygenation during mechanical ventilation. No difference in the rates of the primary endpoint (combination of death or discharge from hospital with poor neurological status) of 32% in the restrictive group and 34% in the liberal oxygenation group, P = 0.69, was found.11 Recently, the EXACT trial compared a strategy adopted for the SaO2 target 90–94% group with that for the 98–100% group.18 The trial was stopped prematurely because of the challenges involved in recruiting patients during the COVID-19 pandemic after the inclusion of 428 patients. Among these patients, 38% were discharged from hospital in the SaO2 90–94% group compared with 48% in the SaO2 target 98–100% group (P = 0.05).18 Therefore, the optimal target of PaO2 in the ICU after resuscitation from OHCA is supported by limited evidence of an optimal oxygenation level but does not challenge the guideline-recommended oxygenations levels of 9–13 kPa or 94–98%. The benefit of moderate hypoventilation or hypercapnia was highlighted in the CCC trial by Eastwood et al.,19 who found significantly lower levels of NSE during the first 48 h in patients with mild hypercapnia. This led to a recently published large-scale clinical trial, the TAME trial, where mild hypercapnia (6.7–7.4 kPa) was compared with normocapnia (4.7–6 kPa) in 1700 patients with OHCA. The primary endpoint was favourable neurological outcome at 6 months, defined as a Glasgow Outcome Scale score of 5–8, which occurred in 44% of patients in the mild hypercapnia group and 45% of patients in the normocapnia group (P = 0.76). Mild hypercapnia was not associated with improved survival rates.20 We, therefore, expect that guidelines remain unaltered for the recommendation of normo-ventilation in mechanically ventilated patients. Mechanical ventilation should target oxygenation levels in the lower normal range, that is, 9–10 kPa, because no benefit for targeting higher levels was found in the BOX trials, and published subgroup analyses have not yet identified specific subgroups of patients in whom higher oxygenation targets were associated with improved outcome.11 Avoiding hyperoxia as well as hypoxia in the post-resuscitation phase remains valid.1 Ventilation should target normal values of PaCO2, that is, 4.5–6 kPa, and lung-protective ventilation strategies using tidal volumes 6–8 mL/kg of ideal body weight seem appropriate.1 The recent TAME trial found no clinically relevant benefit of mild hypercapnia, and therefore, this strategy should not be used.20 Patients resuscitated from cardiac arrest represent a challenge to the treating intensive care staff. Often, the OHCA patient will have a combination of myocardial dysfunction with reduced cardiac output and vasoplegia because of the post-cardiac arrest syndrome. Therefore, the cardiac output should be optimized to ensure that sufficient blood is circulated to maintain oxygen and nutrient delivery sufficient to meet the metabolic demand. Demand may be increased to repair hypoxia-related injury; on the other hand, reperfusion injury, and particularly, high demands placed on the myocardial performance of a person’s heart likely to suffer from ischaemic heart disease, may be detrimental for cardiac recovery and may cause cardiac overload. Monitoring of central or mixed venous oxygenation will provide an insight into the balance between oxygen delivery and consumption and should empirically be targeted >60% (Figure 1). Although cardiovascular function can be supported by vasopressors, such as noradrenalin for increasing vascular tone, blood pressure and afterload, and inodilators, such as dobutamine for increasing cardiac output, the cardiac effect of these pharmacological agents increases myocardial oxygen demand and afterload, which may hamper cardiac recovery and increase the risk of arrythmias. Balancing low afterload for cardiac recovery and an arterial pressure sufficient to support organ function is one of the challenges in post-cardiac arrest care end cardiogenic shock. Traditionally, a target mean arterial blood pressure (MAP) of 65 mmHg is used,1,21 but the evidence for this value is limited. European guidelines state that a systemic MAP sufficient for urine output is recommended,1 and while this target seems physiologically sound, balancing afterload and perfusion pressure, as mentioned above, may be impractical. A MAP of 65 mmHg or more has been the recommended target in most of the recent iterations of guidelines1,21 based on expert consensus and theoretic assumptions of coronary, cerebral, and renal autoregulation. A few smaller observational studies with the risk of uncontrolled bias supported this target by suggesting that mean blood pressure below 60–65 mmHg was associated with an increased risk of death or poor neurological outcome.22–24 In 5 years, four trials have addressed the MAP target in prospective randomized trials, three of which were pilot studies with surrogate endpoints and one was the BOX trial, which was adequately sized to assess the effect on clinical endpoints. First, Jakkula et al.25 published a trial on 123 randomized patients to target an MAP of 65–75 or 80–100 mmHg with an endpoint of mean NSE 48 h post-cardiac arrest. The trial found no differences in the primary endpoint, with 21 and 22 µg/L reported in the two groups. Later, the authors reported that neurofilament concentrations were lower in the 80–100 mmHg target group than in the 65–75 mmHg target group (P = 0.04).26 Second, in 2019, Ameloot et al.27 published their pilot trial on 112 patients, comparing a target MAP of 65 mmHg to an early goal-directed haemodynamic optimization strategy (85–100 mmHg and SVO2 65–75%) with a quantified measure of anoxic brain injury on diffusion-weighted magnetic resonance imaging at Day 5 as a primary endpoint. There was no difference in the rates of the primary endpoint, which were 16 and 12%, and in the odds ratio 1.34 (P = 0.09), nor in any of the prespecified secondary outcomes, although the rates of serious adverse events were lower in patients receiving a target MAP of 85–100 mmHg/SVO2 65–75%.27 Third, a small pilot and feasibility trial compared a target MAP of 65 to 72 mmHg in 50 patients, comparing a plasma concentration of multiple biochemical markers of organ injury, found no difference between the two groups.28 Lastly, the BOX trial compared a target MAP of 63–77 mmHg in a double-blinded intervention in 789 patients undergoing TTM. The rates of primary outcome of death of discharge from hospital with poor neurological outcome at 90 days were 32 and 34% in the two groups (P = 0.56). No differences in the prespecified endpoints of death, neurological outcome, or cognitive outcome at a 3-month follow-up were found. The STEPCARE trial (NCT05564754) has three planned interventions, one of which (the MAPCARE trial) will compare MAP targets of >65 and >85 mmHg in 3500 patients. This trial is expected to start the process of inclusion of patients soon and will provide decisive information for achieving optimal MAP goals in the range of MAPs studied. Whether specific subgroups of patients will benefit from higher blood pressure targets remains to seen. While an increasing number of patients are included in randomized trials, the chances of identifying subgroups of patients in whom higher or lower blood pressure targets are beneficial are more. Further, MAP as a sole target in haemodynamic optimization in severely ill cardiac patients is probably a very elementary approach to efficiently balance the essential measures of afterload or perfusion pressure and perfusion or cardiac output. As part of the BOX trials, we monitored advanced haemodynamics with Swan Ganz catheters and SVO2 and plan to publish substudies based on these variables.29 We believe that optimization in low cardiac output states and then escalating and optimizing treatment to mechanical support is best done with advanced haemodynamic monitoring, echocardiography, and serial measures of lactate and SVO2. Furthermore, a close monitoring of renal function remains a pivotal parameter in intensive care, and care should be taken to optimize renal function and urine output. We suggest monitoring hourly diuresis and fluid balance every 8 h for the first few days of admission, targeting a urine production exceeding 0.5 mL/kg/h. Blood pressure targets should be in the range of 60–65 mmHg, because the BOX trial found no evidence of improved outcomes associated with targeting 77 mmHg MAPs.30 Vasopressors such as noradrenalin and fluid loading of hypovolaemia are relevant interventions to maintain this target. Whether an even higher MAP will prove beneficial in planned trials will be known only from the results of these trials, and the forthcoming MAPCARE trial (NCT05564754) may provide the evidence needed. Monitoring hourly urine output is recommended by guidelines, and this should be part of standard management of these patients.1 Fluid overload should be avoided, but our experience is that a mildly positive fluid balance during TTM will reduce the need for norepinephrine. Sedation during TTM is usually unavoidable, but the target of sedation on the Richmond Agitation and Sedation Scale (RASS) is not well defined. However, it is generally recommended to use analgosedation with short-acting sedatives and opioids to facilitate awakening and neuro-prognostication if necessary.1 Specific recommendations on the levels of sedation are not provided; however, in our experience, deep sedation targeting RASS −4 during TTM is frequently used (Figure 1). While the recommendations in guidelines remain unchallenged by the results of the recent large-scale randomized trials on post-cardiac arrest care, there now seems to be a better awareness of how to achieve treatment goals. The guidelines on TTM continue to be adjusted as more results from the large-scale trials are published, but there is general consensus that an active lowering of body temperature below normal levels should not be performed and preventing fever may be beneficial, although using a fever control device to do so does not seem to alter the outcome.31 There are no new data associated with this article.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart ArrestCardiopulmonary ResuscitationHypothermia, InducedOut-of-Hospital Cardiac ArrestHumansCritical CareHemodynamics

Autor:innen und Institutionen

  • Department of Cardiology, The Heart Center, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, Copenhagen 2100, Denmark.
  • Department of Clinical Medicine, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen, Denmark.
  • Department of Cardiology, Odense University Hospital, JB Winsløvvej 4, Odense 5000, Denmark.

ORCID-Profile: Jesper Kjaergaard

Zitieren

APA

Kjaergaard, J., & Møller, J. E. (2023). Haemodynamic, oxygenation, and ventilation targets after cardiac arrest: the current ABC of post-cardiac arrest intensive care. European Heart Journal: Acute Cardiovascular Care. https://doi.org/10.1093/ehjacc/zuad077

Vancouver

Kjaergaard J, Møller JE. Haemodynamic, oxygenation, and ventilation targets after cardiac arrest: the current ABC of post-cardiac arrest intensive care. European Heart Journal: Acute Cardiovascular Care. 2023. doi:10.1093/ehjacc/zuad077

BibTeX
@article{Kjaergaard2023,
  author = {Kjaergaard, Jesper and Møller, Jacob Eifer},
  title = {Haemodynamic, oxygenation, and ventilation targets after cardiac arrest: the current ABC of post-cardiac arrest intensive care},
  journal = {European Heart Journal: Acute Cardiovascular Care},
  year = {2023},
  doi = {10.1093/ehjacc/zuad077}
}
Kostenlos starten →